Bayesian Capital Management’s Axonics, Inc. Common Stock AXNX Stock Holding History

Bayesian Capital Management’s Portfolio AXNX Stock Details AXNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8,390	Closed	-$471K	–	1081
2023 Q3	$471K	Buy	+8,390	New	+$472K	0.05%	387
2023 Q2	–	Sell	-5,874	Closed	-$320K	–	1118
2023 Q1	$320K	Buy	5,874 +2,500	+74%	+$146K	0.04%	491
2022 Q4	$211K	Buy	+3,374	New	+$224K	0.03%	582
2022 Q2	–	Sell	-4,037	Closed	-$253K	–	1150
2022 Q1	$253K	Buy	+4,037	New	+$218K	0.04%	582

Other funds holding AXNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Bayesian Capital Management's AXNX Position: Q4 2023 in Review

Bayesian Capital Management sold out of Axonics, Inc. Common Stock (AXNX) in Q4 2023, closing a stake of 8,390 shares — an estimated $471K sold.

Bayesian Capital Management first reported a position in AXNX in Q1 2022 and held it in 4 quarters. The position peaked at $471K in Q3 2023. 230 funds tracked by Wall St. Rank hold AXNX as of Q4 2023.

Bayesian Capital Management reported no remaining Axonics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Bayesian Capital Management sold 8,390 Axonics, Inc. Common Stock shares in Q4 2023, an estimated $471K.
Bayesian Capital Management first reported a position in Axonics, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
Bayesian Capital Management's Axonics, Inc. Common Stock position peaked at $471K in Q3 2023.
230 funds tracked by Wall St. Rank held Axonics, Inc. Common Stock as of Q4 2023.

Based on Bayesian Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.